Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-Meg Forte
- Development stage
- Unknown
- Lead developer
- Optho Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
I-Meg Forte is an oral, high-potency antioxidant formulation developed by Optho Pharma for the systemic treatment of severe ocular and related conditions. It is designed as a high-potency successor or stronger variant of the I-Meg 3 formulation, which typically contains a combination of essential eye-health nutrients and antioxidants, including omega-3 fatty acids (such as DHA and EPA), lutein, zeaxanthin, and astaxanthin. These components work synergistically to protect retinal health, filter high-energy blue light, reduce oxidative stress, and support overall visual function. I-Meg Forte is marketed in India for various ocular conditions, including age-related macular degeneration (AMD), dry eye syndrome, cataracts, and glaucoma.
- Brand names
- I-Meg Forte
Beyond the preview
Go deeper on I-Meg Forte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on I-Meg Forte.